To introduce the concept of pathway-focused biomarkers as a translational framework for precision critical care medicine, bridging the gap between omics discoveries and clinical applications.
Approach:
Introduction to Syndromes: Critical care has traditionally been defined by syndromes like sepsis and ARDS, which are biologically heterogeneous, leading to ineffective therapies.
Shift to Biological Subgroups: Recent advances in omics technologies have shifted focus from syndromic labels to biologic subgroups, revealing distinct host-response pathways.
Pathway-Focused Biomarkers: The review proposes pathway-focused biomarkers as biologically informed signatures that can bridge the gap between omics discoveries and clinical applications.
Biomarkers in ICU Practice: Current ICU practice relies on single-analyte markers, but high-dimensional profiling is becoming feasible for bedside decision-making.
Framework for Pathway-Level Analysis: Pathway-focused biomarkers capture coordinated biological activity, distilling complex molecular signals into interpretable readouts.
Key Findings:
Syndromes in critical care are biologically heterogeneous, leading to challenges in clinical trials.
High-dimensional omics technologies can identify distinct biological subphenotypes in critical illness.
Pathway-focused biomarkers can provide actionable insights for clinical decision-making.
Interpretation:
The review highlights the necessity of a unifying framework to effectively translate omics discoveries into actionable therapeutic strategies in critical care.
Limitations:
Technical challenges remain in implementing high-dimensional profiling in clinical settings, including quality control and multiplexing capacity.
A comprehensive understanding of the most relevant pathways and markers is still needed to enhance clinical applicability.
Conclusion:
The promise of the Molecular ICU lies in organizing biological data at the pathway level, which is essential for translating complex molecular signals into practical clinical applications.
